The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease
A Mori, JF Chen, S Uchida, C Durlach, SM King… - Molecules, 2022 - mdpi.com
The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …
pharmacological target for the treatment of neurodegenerative disorders, notably …
An overview of adenosine A2A receptor antagonists in Parkinson's disease
P Jenner - International review of neurobiology, 2014 - Elsevier
Adenosine A 2A receptor antagonists represent a new way forward in the symptomatic
treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class …
treatment of Parkinson's disease (PD) through a non-dopaminergic mechanism. As a class …
Adenosine A2A Receptor Antagonists in Parkinson's Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and …
A Pinna - CNS drugs, 2014 - Springer
Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine,
glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and …
glutamate, adenosine and acetylcholine, are involved in Parkinson's disease (PD) and …
Adenosine A2A Receptor Antagonists for Parkinson's Disease: Rationale, Therapeutic Potential and Clinical Experience
RA Hauser, MA Schwarzschild - Drugs & aging, 2005 - Springer
Long-term disability in Parkinson's disease (PD) is related to progression of the underlying
disease and the emergence of complications of chronic levodopa therapy. There is a need …
disease and the emergence of complications of chronic levodopa therapy. There is a need …
Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists
N Szabo, ZT Kincses, L Vecsei - Expert opinion on drug metabolism …, 2011 - Taylor & Francis
Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder. To
date, most of the currently available therapies in PD target the dopaminergic system and …
date, most of the currently available therapies in PD target the dopaminergic system and …
Adenosine A2A Receptors and Parkinson's Disease
M Morelli, AR Carta, P Jenner - Adenosine receptors in health and disease, 2009 - Springer
The drug treatment of Parkinson's disease (PD) is accompanied by a loss of drug efficacy,
the onset of motor complications, lack of effect on non-motor symptoms, and a failure to …
the onset of motor complications, lack of effect on non-motor symptoms, and a failure to …
The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease
RJ Vorovenci, A Antonini - Expert review of neurotherapeutics, 2015 - Taylor & Francis
The moderate and severe stages of Parkinson's disease (PD) are marked by motor and non-
motor complications that still remain difficult to control with the currently available therapy …
motor complications that still remain difficult to control with the currently available therapy …
Adenosine A2A antagonists in Parkinson's disease: what's next?
P Hickey, M Stacy - Current neurology and neuroscience reports, 2012 - Springer
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder,
affecting up to 10 million people worldwide. Current treatment primarily involves symptom …
affecting up to 10 million people worldwide. Current treatment primarily involves symptom …
Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions
N Simola, M Morelli, A Pinna - Current pharmaceutical design, 2008 - ingentaconnect.com
Adenosine A2A receptors present in the central nervous system have been implicated in the
modulation of motor functions. Accordingly, adenosine A2A receptor antagonists currently …
modulation of motor functions. Accordingly, adenosine A2A receptor antagonists currently …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …